| 引用本文: |
蒋斌,狄奇,贺潇,蒋伟平,刘起立,杨华伟,蔡蔚.马归液联合吉西他滨治疗非肌层浸润型膀胱癌术后的临床观察[J].湖南中医药大学学报,2021,41(8):1275-1279[点击复制] |
|
| |
|
|
| 本文已被：浏览 1609次 下载 554次 |
| 马归液联合吉西他滨治疗非肌层浸润型膀胱癌术后的临床观察 |
| 蒋斌,狄奇,贺潇,蒋伟平,刘起立,杨华伟,蔡蔚 |
| (湖南中医药大学第一附属医院, 湖南 长沙 410007) |
| 摘要: |
| 目的 探讨马归液联合吉西他滨治疗非肌层浸润型膀胱癌（non-muscular invasive bladder cancer，NMIBC）术后的临床疗效及对血清血管内皮生长因子（vascular endothelial growth factor，VEGF）的影响。方法 选取2018年10月至2020年6月在湖南中医药大学第一附属医院泌尿外科住院并符合纳入标准的NMIBC患者66例，根据随机数字表分为观察组（马归液联合吉西他滨治疗）33例，对照组（吉西他滨治疗）33例。比较两组患者术后3、6个月复发率；6个月内不良反应发生率；术前、术后3、6个月安全性评估及血清VEGF水平。结果 两组患者术后6个月复发率均比术后3个月低，观察组术后3、6个月的复发率较对照组低，但差异均无统计学意义（P>0.05）。观察组膀胱刺激症状、血尿、食欲不振的发生率低于对照组（P<0.05），两组患者均出现恶心呕吐和发热的症状，但差异均无统计学意义（P>0.05）。两组患者术前及术后3、6个月内肝肾功能均在正常范围。两组患者术前血红蛋白含量均低于正常值，但差异无统计学意义（P>0.05）；术后3、6个月，观察组的血红蛋白含量显著高于对照组（P<0.05）；术后3个月与术前相比、术后6个月与术后3个月相比，观察组血红蛋白含量均升高（P<0.05）。两组患者术前尿红细胞含量比较差异无统计学意义（P>0.05），但均高于正常值；观察组尿红细胞含量在术后3、6个月均低于对照组（P<0.05）；术后3个月与术前相比、术后6个月与术后3个月相比，两组患者的尿红细胞含量均显著下降（P<0.05），且观察组在术后6个月时尿红细胞含量达到正常水平。两组患者术前血清VEGF水平比较差异无统计学意义（P>0.05）；观察组血清VEGF水平在术后3、6个月低于对照组（P<0.05）；术后3个月与术前相比、术后6个月与术后3个月相比，两组血清VEGF水平均降低（P<0.05）。结论 NMIBC术后行马归液联合吉西他滨膀胱灌注治疗可降低NMIBC术后半年复发率，降低膀胱刺激征、血尿等不良反应，降低VEGF水平，抑制NMIBC复发及预防转移。 |
| 关键词: 非肌层浸润型膀胱癌 马归液 吉西他滨 血管内皮生长因子 膀胱刺激征 |
| DOI：10.3969/j.issn.1674-070X.2021.08.025 |
| 投稿时间：2020-12-16 |
| 基金项目:湖南省科技创新计划项目（2018SK51206）；湖南中医药大学校级科研基金项目（2018XJJJ57）；湖南省教育科学规划院课题项目（XJK015BGD049）。 |
|
| Clinical Observation of Magui Liquid Combined with Gemcitabine in the Treatment of Non-muscular Invasive Bladder Cancer |
| JIANG Bin,DI Qi,HE Xiao,JIANG Weiping,LIU Qili,YANG Huawei,CAI Wei |
| (The First Affiliated Hospital of Hunan University of Chinese medicine, Changsha, Hunan 410007, China) |
| Abstract: |
| Objective To investigate the clinical efficacy of Magui Liquid combined with gemcitabine in the treatment of non-muscular invasive bladder cancer (NMIBC) and its effect on serum VEGF. Methods A total of 66 patients with NMIBC who were hospitalized in the Department of Urology, The First Affiliated Hospital of Hunan University of Chinese Medicine from October 2018 to June 2020 and met the inclusion criteria were selected, and divided into 33 cases of observation group (Magui Liquid combined with gemcitabine treatment) and 33 cases of control group (gemcitabine treatment) according to a random number table. The recurrence rate in 3 and 6 months after operation, adverse reaction rate within 6 months, safety assessment and serum VEGF level in 3 and 6 months after operation were compared between the two groups of patients. Results The recurrence rate of 2 groups was lower at 6 months after surgery than that of 3 months after surgery, and the recurrence rate of the observation group was lower than that of the control group 3 and 6 months after surgery, but the differences were not statistically significant (P>0.05). The incidence of bladder irritation symptoms, hematuria and anorexia in the observation group was lower than that in the control group (P<0.05), and nausea, vomiting and fever were observed in both groups, but there was no statistical significance in the differences (P>0.05). Both groups had normal liver and kidney functions before surgery and 3 and 6 months after surgery. The preoperative hemoglobin content of 2 groups was lower than the normal value, but there was no statistical significance (P>0.05); at 3 and 6 months after operation, the hemoglobin content of observation group was significantly higher than that of control group (P<0.05); the hemoglobin content of the observation group increased 3 months after surgery compared with that before surgery, and 6 months after surgery compared with 3 months after surgery (P<0.05). There was no significant difference in preoperative urine red blood cell content between 2 groups (P>0.05), but both were higher than the normal value; the content of urine red blood cell in observation group was lower than that in control group 3 and 6 months after operation (P<0.05); the urine red blood cell content of 2 groups was significantly decreased 3 months after surgery compared with that before surgery and 6 months after surgery compared with 3 months after surgery (P<0.05), and the observation group urine red blood cell content reached normal level at 6 months after surgery. There was no significant difference in serum VEGF level between 2 groups before surgery (P>0.05); the serum VEGF level in observation group was lower than that in control group 3 and 6 months after operation (P<0.05); serum VEGF levels in both groups were decreased 3 months after surgery compared with that before surgery and 6 months after surgery compared with 3 months after surgery (P<0.05). Conclusion Magui Liquid combined with gemcitabine bladder perfusion for NMIBC after surgery can reduce the recurrence rate of bladder irritation, hematuria, and other adverse reactions and VEGF level, inhibit the recurrence of NMIBC and prevent metastasis. |
| Key words: non-muscular invasive bladder cancer Magui Liquid gemcitabine vascular endothelial growth factor bladder irritation |
|
二维码（扫一下试试看！） |
|
|
|
|
